# ALLBIOSYN

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/allbiosyn

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.allbiosyn.com
- Latest round: Angel (Sep 24, 2025)
- Investors on record: 1

## About

Based in Shanghai, China, ALLBIOSYN is a biotechnology company that specializes in the research and production of nucleotide raw materials for various applications in nucleic acid therapeutics and diagnostics.ALLBIOSYN, founded in 2023, focuses on developing high-quality raw materials for nucleic acid applications. The company operates from its headquarters in Shanghai, China, and has completed one significant deal to date, with its latest deal occurring on September 24, 2025.ALLBIOSYN (??)???????? specializes in the research and production of nucleotide raw materials. Their core offerings include raw materials for oligonucleotide synthesis, materials for gene sequencing, in vitro diagnostic reagents, mRNA vaccine components, and specialized dyes. The company's products are designed to support industries involved in nucleic acid drugs, gene therapy, and diagnostic testing, serving clients in North America, Europe, and Asia.The revenue model of ALLBIOSYN is based on direct business-to-business transactions, providing customized nucleic acid raw materials and technical services. This includes partnerships with pharmaceutical companies and research institutions, involving bulk sales of high-purity phosphoramidite monomers and access to technology platforms. Pricing varies based on client needs, including product volume and complexity.In September 2025, ALLBIOSYN raised an undisclosed amount of Angel funding from Zhuhai Jinwan Jinhang Capital and another investor. The funds will primarily support the R&D and production of key raw materials for nucleic acid drugs, preclinical research, and IND filing for core drugs. The company also plans to enhance its technology platforms, expand its R&D team, and improve laboratory infrastructure, targeting growth in new markets and regions.

## Funding rounds

- Angel, Sep 24, 2025 — Zhuhai Jinwan Jinhang Capital

## Investors

- Zhuhai Jinwan Jinhang Capital (https://capitalatlas.ai/funds/zhuhai-jinwan-jinhang-capital) — Angel